Moleculin Biotech, Inc. (MBRX): Price and Financial Metrics
MBRX Price/Volume Stats
| Current price | $4.28 | 52-week high | $24.75 |
| Prev. close | $4.28 | 52-week low | $4.28 |
| Day low | $4.28 | Volume | 10,408 |
| Day high | $4.42 | Avg. volume | 30,584 |
| 50-day MA | $7.17 | Dividend yield | N/A |
| 200-day MA | $8.14 | Market Cap | 9.53M |
MBRX Stock Price Chart Interactive Chart >
Moleculin Biotech, Inc. (MBRX) Company Bio
Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas.
Latest MBRX News From Around the Web
Below are the latest news stories about MOLECULIN BIOTECH INC that investors may wish to consider to help them evaluate MBRX as an investment opportunity.
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketMoleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor and certain of the Company's executive officers and directors to purchase 7,044,836 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offerin |
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual MeetingMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Company's ongoing European Phase 1B/2 clinical trial evaluating Annamycin for the treatment of acute myeloid leukemia or AML (MB-106) to key opinion leaders and current investigators at a meeting held in conjuncti |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today! |
MBRX Price Returns
| 1-mo | -48.12% |
| 3-mo | -48.29% |
| 6-mo | -51.64% |
| 1-year | -66.71% |
| 3-year | -91.71% |
| 5-year | -95.72% |
| YTD | -66.76% |
| 2023 | -19.02% |
| 2022 | -43.01% |
| 2021 | -61.11% |
| 2020 | -12.89% |
| 2019 | -12.01% |
Loading social stream, please wait...